SHAHID INSAF: Open Payments
NPI 1174666044 · BRANSON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$172,074 in 319 payments from 21 companies in 2025. Trend: 2023 $69,402 · 2024 $97,910 · 2025 $172,074
Honoraria: $71,650Speaker / faculty: $48,440Travel & lodging: $30,777Consulting: $13,168Food & beverage: $8,028Education: $11
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 58 | $53,094 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 45 | $51,011 |
| Supernus Pharmaceuticals, Inc. | 82 | $38,250 |
| Alkermes, Inc. | 40 | $25,612 |
| E.R. Squibb & Sons, L.L.C. | 23 | $1,941 |
| ABBVIE INC. | 9 | $499 |
| Otsuka America Pharmaceutical, Inc. | 12 | $355 |
| Neurocrine BioSciences, Inc. | 13 | $333 |
| Vanda Pharmaceuticals Inc. | 12 | $257 |
| Collegium Pharmaceutical, Inc. | 3 | $171 |
Products named: Auvelity, CAPLYTA, Qelbree, LYBALVI, COBENFY, VRAYLAR, INGREZZA, REXULTI.
Industry payments across MO — which companies pay providers there.
